A US National Health Care System? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : A US National Health Care System?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TimF who wrote (8684)	8/25/2009 5:30:51 PM
From: Alastair McIntosh	Read Replies (3) of 42652

Plenty of incentives for new drugs exist in the European model. Perhaps, but you don't make or quote any argument for that idea. This was the argument for incentives under the European or any other model. If research develops new drugs that provide effective treatments at a lower cost than existing drugs, the new drugs will be marketed. If new drugs are costly on their own but reduce hospital stays and provide treatment at lower overall cost, they will be used. If a new drug is 50% more costly than an existing drug but doubles or triples survival times it will be used. If a drug is developed that offers a five year survival for a cancer that is currently untreatable it will be used. All of the above points illustrate incentives. you might save the final one percent or less of development costs No. Phase II trials pretty much tell if the drug will work as planned and if it is an improvement on current drugs. Most of the cost comes later in Phase III trials (large patient groups and long duration) and the costly regulatory submission.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next